SIOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SIOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Sio Gene Therapies's Gross Profit for the three months ended in Dec. 2022 was $0.00 Mil. Sio Gene Therapies's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, Sio Gene Therapies's Gross Margin % for the quarter that ended in Dec. 2022 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.
The historical rank and industry rank for Sio Gene Therapies's Gross Margin % or its related term are showing as below:
Sio Gene Therapies had a gross margin of N/A% for the quarter that ended in Dec. 2022 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sio Gene Therapies was 0.00% per year.
The historical data trend for Sio Gene Therapies's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sio Gene Therapies Annual Data | |||||||||||||||||
Trend | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||
Gross Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
Sio Gene Therapies Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Gross Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Sio Gene Therapies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sio Gene Therapies's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Sio Gene Therapies's Gross Margin for the fiscal year that ended in Mar. 2022 is calculated as
Gross Margin % (A: Mar. 2022 ) | = | Gross Profit (A: Mar. 2022 ) | / | Revenue (A: Mar. 2022 ) |
= | 0 | / | 0 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (0 - 0) | / | 0 | |
= | N/A % |
Sio Gene Therapies's Gross Margin for the quarter that ended in Dec. 2022 is calculated as
Gross Margin % (Q: Dec. 2022 ) | = | Gross Profit (Q: Dec. 2022 ) | / | Revenue (Q: Dec. 2022 ) |
= | 0 | / | 0 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (0 - 0) | / | 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sio Gene Therapies (OTCPK:SIOX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sio Gene Therapies had a gross margin of N/A% for the quarter that ended in Dec. 2022 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Sio Gene Therapies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Parag V Meswani | officer: Chief Commercial Officer | 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036 |
Pavan Cheruvu | officer: Chief Executive Officer | C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Kristiina Md Vuori | director | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
David W. Nassif | officer: Principal Financial Officer | C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583 |
Senthil Vel Sundaram | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
Dexxon Holdings Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 30600000 |
Andrew Lo | 10 percent owner | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
Svf Investments (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET, LONDON X0 W1K3JP |
Patrick Machado | 10 percent owner | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Qvt Associates Gp Llc | 10 percent owner | 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036 |
Viking Global Performance Llc | 10 percent owner | 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 10-21-2021
By Marketwired Marketwired • 04-28-2021
By Marketwired Marketwired • 06-09-2021
By Marketwired Marketwired • 10-21-2021
By GuruFocusNews GuruFocusNews • 04-27-2022
By Marketwired Marketwired • 10-21-2021
By Marketwired Marketwired • 02-16-2021
By Marketwired Marketwired • 02-04-2021
By Marketwired Marketwired • 05-19-2021
By Marketwired Marketwired • 10-04-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.